of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On June 24, 2026, Absci Corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 13,495,277 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share, to the Underwriters (the “ Offering ”). The Shares w…

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Chief Innovation Officer — Andreas Busch, Ph.D.: Dr. Andreas Busch retired from his role as Chief Innovation Officer but will continue to serve as a scientific advisor.

Entry into a Material Definitive Agreement. On March 6, 2026 the Board of Directors of Absci Corporation (the “ Company ”) approved amended and restated forms of director and officer indemnification agreements (the “A&R Form Indemnification Agreements”) to be entered into by the Company and each of its current directors and officers (which form the Company expects to enter into with future directors and officers) (each, an “ Indemnitee ” and, collectively, the “ Indemnitees ”) in accordance w…

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On October 31, 2025, Absci Corporation (the “ Company ”) executed a Letter Agreement (the “ Letter Agreement ”) with SBGH, LLC (“ SBGH ”), which supplements and amends that certain Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of June 4, 2021, by and among the Company, Target Discovery Merger Sub I, Inc., Target Discovery Merger Sub II, LLC, Totient, Inc., a Delaware corporation (“ Totient ”), and the stockholders named therein.…

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On July 24, 2025, Absci Corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC and TD Securities (USA) LLC (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 16,670,000 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) to the Underwriters…

Director — Mary Szela: Mary Szela was appointed as a Class III director of the Company.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Amrit Nagpal: Mr. Nagpal resigned from the Board of Directors and all committees thereof.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Other Events. Absci Corporation (the "Company") has successfully completed the first milestone in its AI-driven drug discovery collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. The Company successfully delivered AI de novo designed antibody sequences to AstraZeneca in fulfillment of the first milestone under the collaboration, first announced in December 2023. Following election by AstraZeneca, the Company and As…

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K, together with Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On February 27, 2024, Absci Corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Cowen & Company, LLC (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 16,700,000 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) to the Underwriters (the “ Offering ”). Pursuant to the Under…

Other Information. Also on February 27, 2024, the Company filed a preliminary prospectus supplement with the Securities and Exchange Commission under its effective shelf registration statement on Form S-3 (Registration No. 333-267043) (the “Preliminary Prospectus Supplement”) in connection with a proposed registered underwritten public offering of common stock. The Preliminary Prospectus Supplement contains information relating to recent developments concerning the Company’s business and incl…

Results of Operations and Financial Condition. On February 27, 2024, Absci Corporation (the “Company”, “we”, “our”), disclosed preliminary unaudited financial highlights for the three months and year ended December, 31, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Current Report on Form 8-K: • As of December 31, 2023, we had approximately $97.7 million in unrestricted cash and cash equivalents and short-term investments. • For the thre…

Director — Sir Menelas Pangalos: Professor Sir Menelas Pangalos was appointed to the Board of Directors effective January 1, 2024.

Other Events On December 4, 2023, Absci Corporation (the “Company”) issued a press release titled “Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate.” The collaboration agreement described in the press release provides that the Company is entitled to receive an upfront commitment, research and development funding, and milestone payments, collectively totaling up to $247 million, in addition to royalties on product sales. A copy of the press release is atta…